Articles by Walter Armstrong - Pharmaceutical Executive


Articles by Walter Armstrong

Pink Slips and Body Counts

Big Pharma is getting leaner and meaner. Just ask the 100,000 workers laid off since 9/11.
Sep 1, 2007

Ever since Jeffrey Kindler rocked our world last December with the news that Pfizer was cutting its sales force by 10,000, we've been waiting for all the other behemoths' shoes to drop. While no precise domino effect has occurred, downsizing, particularly on the sales side, is very much pharma's strategy du jour.

Tibotec Gets AIDS

With a new wave of "resistant to resistance" HIV drugs, a record of consistent innovation, and a dynamic partnership with AIDS activists, J&J's little company is in it to win it. And end it.
Jul 30, 2007

Tibotec is set to launch a second revolution in HIV treatment—­and make a run at Glaxo, BMS, and Abbott, the longtime market kingpins

Roche to Ventana: "Let's Make A Deal"

Jul 11, 2007

...And the spurned suitor won't take "No" for an answer

Pharma Skinny In Briefs

Jul 11, 2007

It was a short, sweaty week complete with fireworks....

Novartis to Intercell: "Gimme All Your Vax."

Jul 11, 2007

But is the pharma-biotech vaccine deal a prelude to a takeover?

Take Me to Your Leader

Turnover in the top 10 has new CEOs racing to reinvent the way their companies do business. But who has the courage to lead the industry itself back to greatness?
Jul 3, 2007

It's bittersweet being one of the leaders of an industry that is not sustainable," a top pharma CEO recently told Carolyn Buck Luce, Ernst & Young's global pharmaceutical sector leader. Bittersweet is a poignant word for a hard-driving exec to issue.

Merck's Not-So-New Marketing Model

Jul 3, 2007

Or: No news is good news--for everyone but us reporters

Oh Man, Avandia

Think you know the story? Take the test to see what you missed.
Jul 3, 2007

All hell broke loose on May 21 when the New England Journal of Medicine released Cleveland Clinic cardiologist Dr. Steven Nissen's meta-analysis of 42 studies of Avandia, showing a 43 percent increased risk of heart attack.

Fixing the Sales Model

Pharma's new commercialization strategy is, uh, in the works. But what did you expect? Getting it right takes time.
Jun 1, 2007

It was like the end of the arms race last November when Pfizer announced it was slashing its national sales force by 20 percent. Coolly downplayed as cost-cutting by new CEO Jeffrey Kindler, the stunning move was met by industry insiders, Wall Street analysts, and the media with one humongous collective sigh of relief. Big Pharma was seen as having grown dangerously addicted to the detailing game over the past decade, with the top firms plowing more and more of their blockbuster profits into trying to keep up with Pfizer's "flood the zone" strategy and with less and less to show for it.


Click here